Sarah Cannon Research Institute shared on LinkedIn:
“We’re proud to announce a strategic collaboration with Merck to accelerate patient access/enrollment in oncology clinical trials and expand access to cancer research in the communities where patients live and receive care.
At the heart of this partnership is Accelero, SCRI’s integrated trial delivery model.
By streamlining operations and bringing cutting-edge research closer to home, we’re making clinical trials more efficient and more accessible for patients.
This collaboration leverages SCRI’s position as part of McKesson Oncology and Multispecialty, combining research capabilities with industry-leading operational infrastructure to help advance patient care across our network.”
Other articles about SCRI on OncoDaily.